WARNING
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY MEDICINE

Carprieve LA Injection

READ THE ENTIRE LABEL BEFORE USE

PRESENTATION:
Carprieve LA Injection is an injectable solution containing 50mg carprofen per mL. Carprieve LA Injection is a clear sterile solution that is packed in 50mL multi-dose amber glass vials.

INDICATIONS:
Cattle - Carprieve LA Injection is an anti-inflammatory, analgesic and antipyretic agent, and is indicated for the treatment of inflammatory conditions such as acute mastitis and respiratory diseases. In cases of respiratory disease, studies have demonstrated an anti-pyretic effect, with a significantly improved pattern of respiration.
Horses - Carprieve LA Injection is an anti-inflammatory, analgesic and antipyretic agent, and is indicated for the control of post-operative inflammation, and musculoskeletal problems.

DOSAGE & ADMINISTRATION:
Cattle: The recommended dosage is 1.4 mg/kg (1ml/35 kg) bodyweight. This may be given subcutaneously, or by intravenous injection as a single dose.
Horses: The recommended dosage is 0.7 mg/kg (1ml/70 kg) bodyweight. To be administered only by intravenous injection, as a single dose. This dose can be repeated once after 24 hours.

Pharmacokinetic Information -
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) from the arylpropionic acid group of derivatives.
Carpropen is a highly protein-bound substance (<99%), and pharmacokinetic studies in horses and cattle indicate that it has a small volume of distribution, and a slow systemic clearance rate. The plasma elimination half-life in horses and cattle is slow - see below -

Species	Elimination half-life (t ½)
Horses	23.7 to 43.3 hours
Ponies	25.7 to 32.2 hours
Cattle	44.5 to 64.6 hours

Route of excretion -
Horses - mainly urinary excretion
Cattle - biliary secretion, then via the faeces

CONTRAINDICATIONS, WARNINGS:
- FOR INTRAVENOUS USE ONLY IN THE HORSE
- Do not administer by intramuscular injection.
- Do not exceed the stated dose or the duration of treatment.
- Do not administer other NSAIDs concurrently or within 24 hours of each other.
- Toxic effects can occur when drugs that are highly bound to plasma proteins (such as NSAIDs) compete with other highly bound drugs, leading to excess free drug(s) in plasma.
- Do not use where there is a possibility of gastro-intestinal ulceration or bleeding; in animals suffering from cardiac, hepatic or renal disease; or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
- Use in animals less than 6 weeks of age, or in aged animals, may involve additional risk. If prescribed in such cases, animals may require a reduced dosage and careful clinical management.
- Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity.
- Concurrent administration of potential nephrotoxic drugs should be avoided.
- No specific studies have been carried out in pregnant horses, and so use in this class of animal is not indicated.
- NSAIDs can inhibit phagocytosis; therefore appropriate antimicrobial therapy should be given concurrently in the treatment of inflammatory conditions associated with bacterial infection.

Further information -
Drug interaction -
- There have been no significant drug interactions reported in association with carprofen.
- Both carprofen and warfarin may be bound to plasma proteins, but there is evidence that the binding takes place at different sites, allowing concurrent use. However, such concurrent use should be monitored closely.
- In studies involving the use of cattle, carprofen was used in association with four classes of antibiotics (macrolides, tetracyclines, cephalosporins, potentiated penicillins). In these studies, there were no observed interactions.
- Carprofen should not be administered concurrently with any other product of the glucocorticoid or NSAID group.

Safety -
- Horses - carprofen was well tolerated at up to three times the suggested dose rate when administered intravenously on five consecutive days.
- Cattle - carprofen was well tolerated when administered by both the intravenous and subcutaneous route at dose rates of up to five times the suggested dose rate.

WITHHOLDING PERIOD:
It is an offence for users of this product to cause residues exceeding the relevant MRL in the Food Notice: Maximum Residue Levels for Agricultural Compounds.

Milk - Cattle Nil

Meat - Cattle producing meat or offal for human consumption must not be sold for slaughter either during treatment or within **7 days** of the last treatment.
Horses producing meat or offal for human consumption must not be sold for slaughter either during treatment or within **30 days** of the last treatment.

WARNING
Dangerous to the Environment
Handling Precautions:
May be harmful if swallowed. Repeated exposure may cause skin allergy. May possibly affect gastrointestinal tract.
Handle this product with care to avoid oral and skin exposure.
First Aid:
If swallowed do NOT induce vomiting. For advice contact the National Poisons Centre, phone 0800 POISON (0800 764 766) or a doctor immediately.
Environmental Protection:
Harmful to terrestrial vertebrates. Avoid release to the environment.
Disposal:
Preferably dispose of product by use or dispose of product, packaging and waste at an approved landfill or equivalent facility.

STORAGE:
Store below 25°C, protect from light.
Once vial is broached, use contents within 28 days or discard.

Registered pursuant to the ACVM Act 1997 No. A10325
See www.foodsafety.govt.nz for registration conditions.

Registered to & distributed by:
Norbrook NZ Ltd.,
KPMG Centre, 18 Viaduct Harbour Avenue,
Auckland. Ph: 0800 224 022

Manufactured by:
Norbrook Laboratories Ltd.,
Station Works, NEWRY,
Co. Down, Northern Ireland.

019460I04

Norbrook®